<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During 2004-2006, two hypomethylating agents (HMAs) were approved for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the impact of HMAs on the cost of care and survival of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, by constructing a cohort of patients who were diagnosed during 2001-2007 (n=6556, age â‰¥66.5 years) and comparable non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> controls </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients' and controls' Medicare expenditures to derive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related cost </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated the two-year survival of patients as a group and by major subtypes </plain></SENT>
<SENT sid="4" pm="."><plain>Taking into account the survival probabilities of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the expected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related 5-year cost was $63,223 (95% confidence interval: $59,868-66,432 in 2009 dollars), higher than the reported comparable cost for any of the 18 most prevalent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in the United States </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients diagnosed in the earlier period (January 2001-June 2004) who received no HMAs, patients diagnosed later (July 2004-December 2007) who received HMAs had a significantly higher 24-month cost ($97,977 vs. $42,628 in 2009 dollars) and an improved 24-month survival (especially among patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> or <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts) </plain></SENT>
<SENT sid="6" pm="."><plain>The magnitude of the cost of care underscores a need for comparative cost-effectiveness studies to reduce the clinical and economic burden of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>